The Challenge Of Treatment Resistance In Patients With Advanced Egfr Mutated Nsclc

The Challenge Of Treatment Resistance In Patients With Advanced EGFR ...

The Challenge Of Treatment Resistance In Patients With Advanced EGFR ... Based on TROPION-Lung05 results and supported by data from TROPION-Lung01 First and only TROP2-directed therapy approved in the US for the treatment of lung cancer WILMINGTON, Del--(BUSINESS WIRE)-- MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced topline results from the Phase III clinical trial, HARMONi, the first global Phase

Clinical Trials Of ICIs In Patients With Advanced EGFR-mutated NSCLC ...

Clinical Trials Of ICIs In Patients With Advanced EGFR-mutated NSCLC ... (Barcelona, Spain September 6, 2025, 5:45 pm CEST / UTC +2 ) — A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsored by our

Potential Treatment Algorithm For Advanced EGFR-mutated NSCLC Patients ...

Potential Treatment Algorithm For Advanced EGFR-mutated NSCLC Patients ... TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsored by our BERLIN -- Almost half of patients with advanced ALK-positive non-small cell lung cancer (NSCLC) have lived 7 years or longer following initial treatment with the ALK inhibitor alectinib (Alecensa), an REDMOND, Wash and PRINCETON, NJ, Oct 17, 2025 /PRNewswire/ -- SystImmune Inc (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (BMY) today announced the oral DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have

The challenge of treatment resistance in patients with advanced EGFR-mutated NSCLC